Collaboration of CombinatoRx and Fovea for Novel Ophthalmic Therapeutics Built from Synergistic Drug Combinations

02-Feb-2006

CombinatoRx, Incorporated and Fovea Pharmaceuticals SA announced a collaboration for the potential development and commercialization of combination drugs to treat ophthalmic diseases. The agreement unites CombinatoRx's leadership in the systematic discovery of novel combination drug candidates with Fovea's drug development resources and expertise in the field of ophthalmic therapeutics.

Under the terms of the agreement, Fovea has agreed to fund and conduct pre-clinical and clinical development of combination drug candidates it selects from the CombinatoRx portfolio, including creating ophthalmic formulations. Fovea has agreed to develop promising combination candidates up to the start of Phase III clinical trials. In exchange for Fovea's development investment, CombinatoRx will grant to Fovea exclusive commercial rights to selected products in Europe and certain additional countries.

CombinatoRx will jointly own new intellectual property and data generated by Fovea up to Phase III trials and retains the rights to develop and commercialize the ophthalmic products in North America and certain other countries. The parties will have co-exclusive rights in Japan and Taiwan. CombinatoRx and Fovea may choose to jointly pursue Phase III trials and regulatory approval of the product candidates in preparation for launch in their respective territories.

Under the agreement, CombinatoRx will also grant to Fovea an exclusive worldwide license to certain preclinical drug combinations to treat allergic and inflammatory diseases of the front of the eye. For these licensed compounds, CombinatoRx is eligible to receive up to approximately $20 million in upfront and development and regulatory milestone payments for the first product candidate successfully developed, and an additional milestone payment for the approval of a product in an additional indication. CombinatoRx is also eligible to receive royalties for each licensed product commercialized by Fovea.

https://www.bionity.com/en/news/51991/collaboration-of-combinatorx-and-fovea-for-novel-ophthalmic-therapeutics-built-from-synergistic-drug-combinations.html